Esperion’s Bempedoic Acid/ Ezetimibe Tablet Achieves Positive Phase II Results

Treatment developed to lower elevated LDL-C levels in patients with hypercholesterolemia and type 2 diabetes

Esperion announced positive results from the Phase 2 bempedoic acid/ ezetimibe combination tablet study (1002-058). This study assessed the efficacy and safety of the bempedoic acid/ ezetimibe combination tablet compared to ezetimibe and placebo in patients with both hypercholesterolemia and type 2 diabetes.    Esperion’s mission is to deliver once-daily, oral therapies that complement existing oral drugs to provide the additional LDL-C lowering that these patients need. The Phase 2 stud...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters